Arcellx Q4 2024 Earnings Report
Key Takeaways
Arcellx reported positive preliminary data for Anito-cel's iMMagine-1 study with 97% ORR and 62% CR/sCR. They ended the quarter with $626M, reiterating cash runway into 2027. Collaboration revenue was $15.3 million and net losses were $47.1 million for the quarter.
Presented positive preliminary data from the Phase 2 pivotal iMMagine-1 study of anito-cel at ASH 2024, demonstrating a 97% ORR and 62% CR/sCR at a median follow-up of 9.5 months.
Observed no delayed neurotoxicities with anito-cel in 155 patients dosed across Phase 1 and iMMagine-1 studies.
Planned an iMMagine-1 update for presentation mid-year 2025 and a commercial launch of anito-cel in RRMM for 2026.
Ended the quarter with $626M, reiterating cash runway into 2027.
Arcellx
Arcellx
Forward Guidance
Arcellx anticipates presenting updated data from the iMMagine-1 study mid-year 2025, preparing for the commercial launch of anito-cel in multiple myeloma in 2026, enrolling their program in generalized myasthenia gravis, and expanding their ARC-SparX program in acute myeloid leukemia.
Positive Outlook
- Updated data from iMMagine-1 study planned for mid-year 2025 presentation.
- Preparing for commercial launch of anito-cel in multiple myeloma in 2026.
- Enrolling program in generalized myasthenia gravis.
- Expanding ARC-SparX program in acute myeloid leukemia.
- Cash runway into 2027.